Global Cardiac Resynchronization Therapy Systems Market

The Cardiac Resynchronization Therapy Systems Market was USD 4.71 Bn in 2025 and is expected to reach USD 6.54 grow at a CAGR of 4.81% during the forecast period.

Cardiac Resynchronization Therapy Systems Market Overview:

Cardiac Resynchronization Therapy Devices (CRT) are cardiac electrophysiology (EP) systems that include a small electronic device that is surgically implanted into a pocket of skin to help both ventricles contract together. They are also called biventricular pacemakers. These systems can be used for pacing only or can include a built-in defibrillator.

Cardiac Resynchronization Therapy Systems Market Dynamics:

Rising cases of heart failure worldwide is the main factor driving the market growth.

Cases of heart failure are rising exponentially due to change in lifestyle and various factors such as malnutrition, genetic mutations, and others. Globally 26 million people are affected by heart failure. Along with this, the rise in the demand for invasive techniques in the treatment of heart diseases, advancements in technologies, and the rise in the adaptability of CRT devices are fuelling the market growth. Adaptation of sedentary lifestyle leads to the high prevalence of high blood pressure, high cholesterol, obesity, alcohol consumption, which results in high incidence of cardiovascular diseases also propels the growth of CRT systems market.To Know About The Research Methodology:- Request Free Sample Report

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Cardiac Resynchronization Therapy Systems Market Segment Analysis:

The Global Cardiac Resynchronization Therapy Systems Market is segmented on the basis of product and end-users.

Based on Product, the market is segmented into Cardiac Resynchronization Therapy Defibrillator and Cardiac Resynchronization Therapy Pacemaker. Cardiac Resynchronization Therapy Defibrillator held the largest market share of xx% in 2025 and is expected to continue the dominance throughout the forecast period.This device is recommended for people with heart failure who also have a risk of sudden cardiac death. It can detect dangerous heart rhythms and deliver a stronger shock of energy, which is able to reset your heartbeat than a pacemaker can deliver. On 19th February 2021, Abbott Laboratories received a CE mark for its two devices Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D).

Cardiac Resynchronization Therapy Systems Market Regional Insights:

North America is expected to lead the global market for CRT Systems, followed by Europe.

Owing to the rising prevalence of cardiac diseases, obesity hypertension issues in the region attribute to the largest market share. Besides this, well-established medical infrastructure, high healthcare expenditures, substantial investments in R&D activities by the public and private sector, and rising demand for technologically advanced cardiac monitoring & cardiac rhythm management devices augment the market growth.

APAC market is expected to grow at a steady pace during forecast years.

The prevalence of cardiac disorders growing at a higher rate, alongside the growing number of an aging population, drives the APAC CRT market. Also, the adaptation of advanced healthcare technology, government initiatives to improve the quality of healthcare, and favorable reimbursement policies propel the growth of the regional market. Various technological developments in the healthcare industry in the Asia Pacific are expected to offer growth opportunities for the players operating in the cardiac resynchronization therapy market.

The report also helps in understanding Global Cardiac Resynchronization Therapy Systems Market dynamics, structure by analyzing the market segments and project the Global Cardiac Resynchronization Therapy Systems Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Cardiac Resynchronization Therapy Systems Market make the report investor’s guide.

Cardiac Resynchronization Therapy Systems Market Scope: Inquire before buying

Recent Development

• In April 2025, EBR Systems, Inc. received FDA approval for its leadless WiSE CRT System, a wireless pacing solution that eliminates traditional leads, reducing complications and broadening therapy eligibility.
• MicroPort CRM launched the GALI™ SonR® CRT-D device with NAVIGO™ 4LV left ventricular pacing leads in Japan and other key markets, featuring hemodynamic sensors for automatic pacing optimization.

Cardiac Resynchronization Therapy Systems Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Key Players/Competitors Profile, Covered in The The Cardiac Resynchronization Therapy Systems Market  Report, From A Strategic Perspective

1. Medtronic
2. Boston Scientific Corporation
3. Abbott Laboratories
4. LivaNova PLC
5. BIOTRONIK SE & Co. KG
6. MicroPort Scientific Corporation
7. Medico S.p.A.
8. NIHON KOHDEN CORPORATION
9. Koninklijke Philips N.V.
10. Lepu Medical Technology Co., Ltd.
11. Japan Lifeline Co., Ltd.
12. Shree Pacetronix Ltd.
13. St. Jude Medical
14. Accellent Inc.
15. Osypka Medical GmbH
16. ZOLL Medical Corporation
17. Sorin Group
18. Cardinal Health, Inc.
19. GE Healthcare
20. Siemens Healthineers AG
21. Johnson & Johnson
22. Edwards Lifesciences Corporation
23. Integer Holdings Corporation
24. Asahi Kasei Corporation
25. EBR Systems, Inc.